98%
921
2 minutes
20
Background And Aim Of The Study: The study aim was to assess the characteristics of bacterial endocarditis complicating mitral annulus calcification, and to evaluate the surgical results.
Methods: Twenty-four patients (mean age 64 years) underwent surgery for mitral insufficiency secondary to mitral endocarditis with annulus calcification (acute, n = 18; healed, n = 6). Surgery was performed as an emergency in seven cases for septic (n = 3) or cardiogenic (n = 4) shock. An aortic prosthesis had previously been placed in three cases. Comorbidities noted included chronic renal insufficiency/dialysis (n = 8), cancer (n = 6), coronary disease (n = 6), and obstructive cardiomyopathy (n = 1). Nine patients suffered an embolic complication, such as stroke (n = 7, of which three had coma), splenic (n = 3), or lower limb (n = 1). The microorganism present was identified as Staphylococcus aureus (n = 9), Streptococcus/ Enterococcus sp. (n = 12), or others (n = 3). The left atrial diameter was 48 mm, the ejection fraction 63%, and the septal thickness 13 mm.
Results: The mean severity score of annulus calcifications (range: 1 to 5) was 1.9. The anatomical lesions included: vegetations (n = 16, of which eight were > 10 mm), leaflet perforation (n = 9), chordae rupture (n = 9), aortic abscess (n = 2) and mitral annular abscess (n = 9), and one fistulation into the pericardium. The valve was repaired in 15 cases, and replaced in nine (seven bioprostheses, two mechanical). Associated procedures included aortic valve replacement (n = 7) and coronary artery bypass (n = 3). The in-hospital mortality was 29% (n = 7); all patients who died were operated on during the acute phase. All patients who presented with septic shock or coma died. After a mean follow up of 46 months, six patients had died (overall survival was 46% at 33 months), and 11 were in NYHA class I/II. One recurrence of endocarditis was treated medically.
Conclusion: Bacterial endocarditis complicating mitral annulus calcification has a poor prognosis due to the frequent comorbidity and severity of the infectious complications. Patients in septic shock or coma do not appear to be suitable candidates for surgery. Valve repair was possible in two-thirds of the present patients; otherwise, a bioprosthetic replacement was the option of choice.
Download full-text PDF |
Source |
---|
Tissue Eng Part A
September 2025
Department of Orthopaedic Surgery, McKay Orthopaedic Research Laboratory, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Cell and tissue engineering therapies provide promise for regenerating damaged intervertebral disc (IVD) tissue and resolving the low back pain that often accompanies it. However, these treatments remain experimental and unavailable for patients. Furthermore, the large body of work characterizing and utilizing mesenchymal stromal cells (MSCs) for these applications has, unfortunately, not resulted in any FDA-approved spinal therapies.
View Article and Find Full Text PDFStruct Heart
August 2025
Cardiology Department, Bichat Claude Bernard Hospital, Paris, France.
JACC Case Rep
August 2025
Cardiovascular Center Surgery Department, Toranomon Hospital, Tokyo, Japan.
Background: Caseous calcification of the mitral annulus (CCMA), a rare variant of mitral annular calcification, is occasionally associated with calcified amorphous tumors (CATs). These distinctive lesions are poorly documented, particularly regarding their potential for mobility and embolism.
Case Summary: A 73-year-old woman presented with acute left-sided hemiparesis and dysarthria.
Echocardiography
August 2025
Division of Cardiovascular Medicine, Department of Internal Medicine, Jichi Medical University, Shimotsuke, Tochigi, Japan.
This case highlights a rare yet clinically significant complication of caseous calcification of the mitral annulus (CCMA), wherein three-dimensional transesophageal echocardiography clearly delineated a left ventricular-to-left atrial fistula secondary to CCMA rupture, resulting in hemolytic anemia.
View Article and Find Full Text PDFCardiovasc Revasc Med
August 2025
School of Medicine, European University Cyprus, Nicosia, Cyprus; 3(rd) Department of Cardiology, Euroclinic of Athens, Athens, Greece.
Mitral regurgitation (MR) remains a prevalent and undertreated condition, particularly in patients at high surgical risk or unsuitable for mitral transcatheter edge-to-edge repair (M-TEER). The HighLife (HighLife SAS, Paris, France) transcatheter mitral valve replacement (TMVR) system offers a novel solution with its unique two-component design comprising a subannular ring and a self-expanding bioprosthetic valve. Delivered via a transfemoral arterial and transseptal venous approach, this "valve-in-ring" system enables circumferential anchoring without the need for annular calcification or transapical access.
View Article and Find Full Text PDF